Millepachine
Based on 1 Customer Validation
Millepachine is a bioactive natural chalcone from Chinese herbal medicine Millettia pachycarpa Benth, exhibits strong antitumor effects against numerous human cancer cells both in vitro and in vivo.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.81%
- CAS No.: 1393922-01-4
- Formule: C22H22O4
- Masse moléculaire:350.41
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
3.09 μM
Compound: Millepachine
|
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| A-375 | IC50 |
3.58 μM
Compound: Millepachine
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 23425970] |
| A-375 | IC50 |
3580 nM
Compound: 1
|
Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| A549 | IC50 |
>10 μM
Compound: Millepachine
|
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 38452727] |
| A549 | IC50 |
3.95 μM
Compound: Millepachine
|
Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| HCT-116 | IC50 |
4.66 μM
Compound: Millepachine
|
Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| HCT-8 | IC50 |
5.02 μM
Compound: Millepachine
|
Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| HeLa | IC50 |
6.03 μM
Compound: Millepachine
|
Antiproliferative activity against human HeLa cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| HepG2 | IC50 |
1.51 μM
Compound: Millepachine
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| HepG2 | IC50 |
1.51 μM
Compound: Millepachine
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 23425970] |
| HepG2 | IC50 |
1.51 μM
Compound: Millepachine
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 24629450] |
| HepG2 | IC50 |
1.51 μM
Compound: 5
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
|
[PMID: 31539776] |
| HepG2 | IC50 |
1510 nM
Compound: 1
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HepG2 | IC50 |
4.54 μM
Compound: 1a
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| HT-29 | IC50 |
3.29 μM
Compound: Millepachine
|
Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| K562 | IC50 |
4.56 μM
Compound: Millepachine
|
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| K562 | IC50 |
4.56 μM
Compound: Millepachine
|
Cytotoxicity against human K562 cells by MTT assay
Cytotoxicity against human K562 cells by MTT assay
|
[PMID: 23425970] |
| K562 | IC50 |
4560 nM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| L02 | IC50 |
>20 μM
Compound: Millepachine
|
Cytotoxicity against human LO2 cells by MTT assay
Cytotoxicity against human LO2 cells by MTT assay
|
[PMID: 23425970] |
| L02 | IC50 |
25.05 μM
Compound: 1a
|
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| MCF7 | IC50 |
4.37 μM
Compound: Millepachine
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 38452727] |
| MCF7 | IC50 |
6.98 μM
Compound: Millepachine
|
Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| MDA-MB-231 | IC50 |
2.47 μM
Compound: Millepachine
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
[PMID: 38452727] |
| MGC-803 | IC50 |
10.98 μM
Compound: 1a
|
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| NCI-H460 | IC50 |
7.65 μM
Compound: 1a
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| PC-3 | IC50 |
1.13 μM
Compound: Millepachine
|
Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells incubated for 72 hrs by MTT assay
|
[PMID: 38452727] |
| SK-OV-3 | IC50 |
2.36 μM
Compound: Millepachine
|
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| SK-OV-3 | IC50 |
9.85 μM
Compound: 1a
|
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| SW-620 | IC50 |
0.76 μM
Compound: Millepachine
|
Antiproliferative activity against human SW620 cells after 24 hrs by MTT assay
Antiproliferative activity against human SW620 cells after 24 hrs by MTT assay
|
[PMID: 22784822] |
| T-24 | IC50 |
11.05 μM
Compound: 1a
|
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| U-251 | IC50 |
3.72 μM
Compound: Millepachine
|
Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human U-251 cells incubated for 72 hrs by MTT assay
|
[PMID: 38452727] |
Millepachine (1.25-20 μM; 48 h) remarkably inhibits the proliferation of cisplatin-resistant A2780CP cells[1].
Millepachine (2-8 μM; 24 or 48 h) induces G2/M arrest and apoptosis cisplatin-sensitive A2780S and cisplatin-resistant A2780CP cells[1].
Millepachine (2-8 μM; 24 h) decreases topoisomerase II levels in A2780S and A2780CP cells[1].
Millepachine (2-8 μM; 24 h) inhibits ATP-binding cassette transporter activity in A2780CP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A2780CP cells
-
Concentration:0, 1.25, 2.5, 5, 10, 20 μM
-
Incubation Time:48 hours
-
Result:Inhibited the cells proliferation with an IC50 of 4 μM.
-
Cell Line:A2780S and A2780CP cells
-
Concentration:2, 4, 8 μM
-
Incubation Time:24 or 48 hours
-
Result:Induced significant G2/M arrest both in both cells.
The percentage of cells in the G2/M fraction increased from 15.99% in vehicle cells to 24.93%, 60.67%, and 77.31% at dose of 2, 4, and 8 μM in A2780S cells, respectively.
-
Cell Line:A2780S and A2780CP cells
-
Concentration:2, 4, 8 μM
-
Incubation Time:24 or 48 hours
-
Result:The percentage of apoptotic cells increased from 1.49% in vehicle cells to 10.98%, 20.60%, and 39.43% at dose of 2, 4, and 8 μM in A2780S cells, respectively.
The percentage of apoptotic cells increased from 0.87% to 10.97%, 25.28%, and 37.59% in A2780CP cells, respectively.
-
Cell Line:A2780S and A2780CP cells
-
Concentration:0, 2, 4, 8 μM
-
Incubation Time:24 hours
-
Result:Decreased the levels of topoisomerase II (TOPO II) in both cells.
Millepachine (20 mg/kg; i.v. every two days for 14 day) does not induce acquired drug resistance in an excised A2780S xenograft model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (6 weeks) are injected A2780S or A2780CP cells[1]
-
Dosage:20 mg/kg
-
Administration:I.v. every two days for 2-14 days
-
Result:Reduced tumor volume and tumor weight with the inhibitory rate of 73.21% and 65.58% in A2780S (after seven times injection) and A2780CP (after six times injection) xenograft model, respectively.
With low toxicity in vivo.
Chemical Information
-
CAS No. 1393922-01-4
-
Appearance Solid
-
Masse moléculaire 350.41
-
Formule C22H22O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C2C(C=CC(C)(C)O2)=C(OC)C=C1)/C=C/C3=CC=C(OC)C=C3
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (285.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (5.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2 mg/mL (5.71 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8538 mL | 14.2690 mL | 28.5380 mL | 71.3450 mL |
| 5 mM | 0.5708 mL | 2.8538 mL | 5.7076 mL | 14.2690 mL | |
| 10 mM | 0.2854 mL | 1.4269 mL | 2.8538 mL | 7.1345 mL | |
| 15 mM | 0.1903 mL | 0.9513 mL | 1.9025 mL | 4.7563 mL | |
| 20 mM | 0.1427 mL | 0.7134 mL | 1.4269 mL | 3.5672 mL | |
| 25 mM | 0.1142 mL | 0.5708 mL | 1.1415 mL | 2.8538 mL | |
| 30 mM | 0.0951 mL | 0.4756 mL | 0.9513 mL | 2.3782 mL | |
| 40 mM | 0.0713 mL | 0.3567 mL | 0.7134 mL | 1.7836 mL | |
| 50 mM | 0.0571 mL | 0.2854 mL | 0.5708 mL | 1.4269 mL | |
| 60 mM | 0.0476 mL | 0.2378 mL | 0.4756 mL | 1.1891 mL | |
| 80 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.8918 mL | |
| 100 mM | 0.0285 mL | 0.1427 mL | 0.2854 mL | 0.7134 mL |